Experimental drug offers hope for Tough-to-Treat blood cancers

NCT ID NCT06618001

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called JNJ-89853413 in people with advanced forms of blood cancer that have returned or stopped responding to previous treatments. The main goals are to determine safe dosage levels and see how well the drug is tolerated. Researchers will enroll 115 participants with either acute myeloid leukemia or myelodysplastic neoplasms to gather initial safety and effectiveness data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Addenbrookes Hospital
RECRUITING

Cambridge, Cb2 2qq, United Kingdom
Arthur J E Child Comprehensive Cancer Centre
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Clinica Univ. de Navarra
RECRUITING

Pamplona, 31008, Spain
Hosp Clinic de Barcelona
RECRUITING

Barcelona, 08036, Spain
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Princess Margaret Hospital
RECRUITING

Toronto, Ontario, M5G 2C1, Canada
The Christie NHS Foundation Trust Christie Hospital
RECRUITING

Manchester, M20 4BX, United Kingdom
University College London Hospitals
RECRUITING

London, W1T 7HA, United Kingdom
Vancouver General Hospital
RECRUITING

Vancouver, British Columbia, V5Z 1M9, Canada

Conditions

Explore the condition pages connected to this study.

LEUKEMIA, MYELOID, ACUTE MYELODYSPLASTIC NEOPLASMS